Clinical-biologic features and related outcome (EFS estimated [SE] at 5 years from diagnosis) in 464 T-ALL patients according to MRD classification
| . | MRD-SR . | MRD-IR . | MRD-HR . | Total N . | |||
|---|---|---|---|---|---|---|---|
| N (%) . | 5-year EFS (SE) . | N (%) . | 5-year EFS (SE) . | N (%) . | 5-year EFS (SE) . | ||
| Total | 75 (16.2) | 93.0 (3.0) | 292 (62.9) | 80.6 (2.3) | 97 (20.9) | 49.8 (5.1) | 464 |
| Sex | |||||||
| Male | 52 (15.2) | 90.1 (4.2) | 219 (63.8) | 79.6 (2.8) | 72 (21.0) | 53.6 (5.9) | 343 |
| Female | 23 (19.0) | 100.0 | 73 (60.3) | 83.5 (4.3) | 25 (20.7) | 39.0 (9.9) | 121 |
| Age, y | |||||||
| 1-9 | 36 (14.6) | 88.7 (5.3) | 160 (64.8) | 84.2 (2.9) | 51 (20.6) | 48.2 (7.1) | 247 |
| 10-17 | 39 (18.0) | 97.4 (2.5) | 132 (60.8) | 76.4 (3.7) | 46 (21.2) | 51.7 (7.4) | 217 |
| WBC count, /μL | |||||||
| < 100 000 | 58 (21.3) | 94.8 (2.9) | 170 (62.5) | 82.9 (2.9) | 44 (16.2) | 49.5 (7.6) | 272 |
| ≥ 100 000 | 17 (8.9) | 87.8 (8.1) | 122 (63.5) | 77.6 (3.8) | 53 (27.6) | 50.2 (6.9) | 192 |
| Response to prednisone | |||||||
| PGR | 71 (23.8) | 94.1 (2.9) | 194 (65.1) | 83.9 (2.6) | 33 (11.1) | 59.1 (8.8) | 298 |
| PPR | 4 (2.5) | — | 94 (59.1) | 74.0 (4.6) | 61 (38.4) | 44.3 (6.4) | 159 |
| Not known | 0 | — | 4 (57.1) | — | 3 (42.9) | — | 7 |
| Final stratification AIEOP-BFM 2000 | |||||||
| SR | 71 (100.0) | 94.1 (2.9) | 0 | — | 0 | — | 71 |
| IR | 0 | — | 198 (100.0) | 83.8 (2.6) | 0 | — | 198 |
| HR | 4* (2.1) | — | 94† (48.2) | 74.0 (4.6) | 97 (49.7) | 49.8 (5.1) | 195 |
| T-ALL subtype | |||||||
| Early | 6 (5.7) | — | 68 (64.1) | 65.6 (5.9) | 32 (30.2) | 46.9 (8.8) | 106 |
| Cortical | 66 (24.2) | 92.1 (3.4) | 171 (62.6) | 85.9 (2.7) | 36 (13.2) | 50.8 (8.6) | 273 |
| Mature | 2 (2.8) | — | 42 (59.2) | 80.8 (6.1) | 27 (38.0) | 48.2 (9.6) | 71 |
| Not specified | 1 (7.1) | — | 11 (78.6) | — | 2 (14.3) | — | 14 |
| . | MRD-SR . | MRD-IR . | MRD-HR . | Total N . | |||
|---|---|---|---|---|---|---|---|
| N (%) . | 5-year EFS (SE) . | N (%) . | 5-year EFS (SE) . | N (%) . | 5-year EFS (SE) . | ||
| Total | 75 (16.2) | 93.0 (3.0) | 292 (62.9) | 80.6 (2.3) | 97 (20.9) | 49.8 (5.1) | 464 |
| Sex | |||||||
| Male | 52 (15.2) | 90.1 (4.2) | 219 (63.8) | 79.6 (2.8) | 72 (21.0) | 53.6 (5.9) | 343 |
| Female | 23 (19.0) | 100.0 | 73 (60.3) | 83.5 (4.3) | 25 (20.7) | 39.0 (9.9) | 121 |
| Age, y | |||||||
| 1-9 | 36 (14.6) | 88.7 (5.3) | 160 (64.8) | 84.2 (2.9) | 51 (20.6) | 48.2 (7.1) | 247 |
| 10-17 | 39 (18.0) | 97.4 (2.5) | 132 (60.8) | 76.4 (3.7) | 46 (21.2) | 51.7 (7.4) | 217 |
| WBC count, /μL | |||||||
| < 100 000 | 58 (21.3) | 94.8 (2.9) | 170 (62.5) | 82.9 (2.9) | 44 (16.2) | 49.5 (7.6) | 272 |
| ≥ 100 000 | 17 (8.9) | 87.8 (8.1) | 122 (63.5) | 77.6 (3.8) | 53 (27.6) | 50.2 (6.9) | 192 |
| Response to prednisone | |||||||
| PGR | 71 (23.8) | 94.1 (2.9) | 194 (65.1) | 83.9 (2.6) | 33 (11.1) | 59.1 (8.8) | 298 |
| PPR | 4 (2.5) | — | 94 (59.1) | 74.0 (4.6) | 61 (38.4) | 44.3 (6.4) | 159 |
| Not known | 0 | — | 4 (57.1) | — | 3 (42.9) | — | 7 |
| Final stratification AIEOP-BFM 2000 | |||||||
| SR | 71 (100.0) | 94.1 (2.9) | 0 | — | 0 | — | 71 |
| IR | 0 | — | 198 (100.0) | 83.8 (2.6) | 0 | — | 198 |
| HR | 4* (2.1) | — | 94† (48.2) | 74.0 (4.6) | 97 (49.7) | 49.8 (5.1) | 195 |
| T-ALL subtype | |||||||
| Early | 6 (5.7) | — | 68 (64.1) | 65.6 (5.9) | 32 (30.2) | 46.9 (8.8) | 106 |
| Cortical | 66 (24.2) | 92.1 (3.4) | 171 (62.6) | 85.9 (2.7) | 36 (13.2) | 50.8 (8.6) | 273 |
| Mature | 2 (2.8) | — | 42 (59.2) | 80.8 (6.1) | 27 (38.0) | 48.2 (9.6) | 71 |
| Not specified | 1 (7.1) | — | 11 (78.6) | — | 2 (14.3) | — | 14 |